Investment Rating - The industry rating is "Overweight" [3] Core Insights - The report highlights the ongoing active research in life sciences and the rapid integration of biotechnology into economic and social development, providing innovative solutions to major challenges such as health, climate change, resource security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for the Development of the Bioeconomy," indicating a trillion-yuan market potential in the bioeconomy sector [3][4]. Industry Performance - The Huazhong Synthetic Biology Index increased by 0.11% to 1278.44 during the week of February 2-6, 2026, outperforming the Shanghai Composite Index by 1.39 percentage points and the ChiNext Index by 3.40 percentage points [4]. - The report notes that the synthetic biology sector is experiencing a policy dividend, with Shenzhen proposing up to 100 million yuan in support for R&D efforts in the field [8]. Company Developments - Beijing Huaguan Bio completed a multi-hundred million yuan C-round financing to enhance its R&D and production capabilities in the pharmaceutical and health sectors [32]. - Dejin Bio secured several million yuan in A-round financing to advance its recombinant botulinum toxin clinical research and international expansion [33]. - The report mentions that Impossible Foods is leveraging technology to reshape the plant protein market [11]. Market Dynamics - The report indicates that the synthetic biology sector is witnessing a surge in financing, with nearly a hundred companies completing new funding rounds since 2025 [31]. - The top five companies in the synthetic biology sector by stock performance during the week were Pingtan Development (+12%), Jinbo Bio (+12%), Huaxi Bio (+12%), Shandong Heda (+10%), and Yaxiang Co. (+10%) [17]. Policy and Regulatory Developments - The Ministry of Industry and Information Technology announced 35 examples of non-grain bio-based materials, marking a significant step towards establishing a new green development framework [7]. - The National Health Commission approved 22 new food items, including a significant breakthrough in domestic human milk oligosaccharides (HMOs) production [7]. Research and Innovation - Tsinghua University has initiated a national key R&D project focused on the intelligent design principles of efficient microbial chassis cells, aiming for breakthroughs in both fundamental theory and application demonstration [9]. - The report highlights the strategic cooperation between Tianjin University and China National Petroleum Corporation to expand efforts in synthetic biology and related fields [9].

Investment Rating - The industry investment rating is "Overweight" [3] Core Insights - The report highlights the ongoing active research in life sciences and the accelerating integration of biotechnology into economic and social development, providing new solutions to major challenges such as health, climate change, resource security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for the Development of the Bioeconomy," indicating a trillion-yuan market potential in the bioeconomy sector [3][7]. Industry Performance - The Huazhong Synthetic Biology Index increased by 0.11% to 1278.44 during the week of February 2-6, 2026, outperforming the Shanghai Composite Index by 1.39 percentage points and the ChiNext Index by 3.40 percentage points [4][14]. - The report notes that the synthetic biology sector is experiencing a policy dividend, with Shenzhen proposing up to 100 million yuan in support for R&D efforts in the field [8]. Company Developments - Beijing Huaguan Bio completed a multi-hundred million yuan C-round financing to focus on new product development in the pharmaceutical and health sectors [31]. - Dejin Bio secured several million yuan in A-round financing to advance its recombinant botulinum toxin clinical research and international expansion [33]. - The report mentions that Impossible Foods is leveraging technology to drive market expansion and reshape plant-based protein [11]. Market Dynamics - The report indicates that the synthetic biology sector is witnessing a surge in financing, with nearly a hundred companies completing new rounds of financing since 2025 [31]. - The top five companies in the synthetic biology sector by stock performance during the week were Pingtan Development (+12%), Jinbo Bio (+12%), Huaxi Bio (+12%), Shandong Heda (+10%), and Yaxiang Co. (+10%) [17][21]. Policy and Regulatory Updates - The Ministry of Industry and Information Technology announced 35 examples of non-grain bio-based materials, marking a significant step towards building a new green development pattern [7]. - The National Health Commission approved 22 new food products, including a significant breakthrough in domestic human milk oligosaccharides (HMOs) technology [7]. Research and Innovation - Tsinghua University has initiated a national key R&D project focused on the intelligent design principles of efficient microbial chassis cells, aiming for breakthroughs in both fundamental theory and application demonstration [9]. - The report highlights the strategic cooperation between Tianjin University and China National Petroleum Corporation to expand in synthetic biology and other fields [9].

【SynBioCon】 获 悉， 2月6日，专注于植物细胞底盘合成生物技术的 神笔生物 ，正式完成 数千万元Pre-A轮融资 ，由百联挚高独家领投。资金 将主要用于 " 植物细胞底盘合成生物平台的技术迭代、核心产品产业化落地及市场拓展 "。 神笔生物为人所知的标签，是其在2024年成功培育出的 国内首株高亮度、性状稳定的自发光植物 。 神笔生物 自发光植物 01 技术破壁：532次实验背后的"追光"之旅 据合肥在线2024年8月的报道，神笔生物团队为实现这一目标， 进行了长达一年多的研发，共经历了532次关键实验迭代 。 从最初需要长时间手机曝光才能捕捉到微弱光迹，到最终实现肉眼清晰可见的稳定亮度，每一次迭代都是对基因通路、转化效率和植物 性状的极致 优化。 关键词| 资本事件 | 神笔生物 此次融资的特别之处在于，它投向了一个将前沿基因编辑技术转化为 可见、可感、可消费 产品的企业。 其技术核心在于，将自然界中发光生物（如某些真菌或海洋生物）的 荧光素酶基因 ，通过基因编辑技术整合进植物的基因组。 这些外源基因在植物体内成功表达，催化一系列生化反应，最终将化学能转化为可见光，实现植物的"自发光"。 "这个数 ...

Summary of Industry Reports Industry: Pharmaceutical and Biotechnology Key Points from Document 1 1. **Raw Material Supply Changes**: The supply of raw materials is accelerating, with a focus on subsequent volume and price changes [1] 2. **Global GLP-1 Landscape**: The global GLP-1 landscape is continuously evolving, and Chinese companies are still pursuing international expansion [1] 3. **Small Nucleic Acid Sector**: Leading companies are gradually entering the small nucleic acid field, with market progress expected to drive the development of supporting industrial chains [1] 4. **Retail Pharmaceutical Market Outlook**: The retail pharmaceutical market is expected to improve by Q4 2025, with an enhanced positioning of chain pharmacies [1] 5. **Value of Oral Immunomodulatory Drugs**: Emphasis on the market value of oral immunomodulatory drugs [1] 6. **Investment Recommendations**: Recommended companies include Chuaning Biological, with attention to Lianbang Pharmaceutical, Guobang Pharmaceutical, and Puluo Pharmaceutical, as well as synthetic biology companies [1] 7. **CXO Order Trends**: Positive trends in CXO orders and rising prices for safety evaluation orders, with recommendations for Yinos and Zhaoyan New Drug, and recommendations for Weiya Biological and Puris [1] Key Points from Document 2 1. **Small Nucleic Acids Breakthrough**: Continuous breakthroughs in small nucleic acids, with ongoing progress in external authorizations by Chinese companies, recommending Yuekang Pharmaceutical and Sunshine Novo [2] 2. **Self-Immunity Field**: Focus on breakthroughs in oral directions and difficult-to-treat areas like UC/IBD, recommending Yahong Pharmaceutical and Yifang Biological [2] 3. **GLP-1 Weight Loss Authorizations**: Recommendations for Zhongsheng Pharmaceutical in the GLP-1 weight loss field, with attention to Lianbang Pharmaceutical and Shiyao Group [2] 4. **ZAP-X Radiation Therapy Equipment**: Initiation of domestic clinical research for ZAP-X radiation therapy equipment, recommending Baiyang Pharmaceutical [2] 5. **Policy Support for Brain-Computer Interface Technology**: Support for the development of invasive brain-computer interfaces, recommending Meihao Medical and Botuo Biological, with accelerated approvals for non-invasive devices, focusing on Xiangyu Medical and Kefu Medical [2] 6. **High-Value Medical Device Exports**: Breakthroughs in exports of high-value medical consumables, with attention to Chunli Medical, Aikang Medical, Nanwei Medical, and Baixin An [2] 7. **AI in Healthcare**: Accelerated applications of AI in healthcare, reshaping application scenarios and bringing changes in industrial chain value, recommending Anbiping and focusing on Yuyue Medical and Meinian Health [2] 8. **Chain Pharmacy Industry**: Industry consolidation in chain pharmacies, with policy support for enhanced positioning, recommending Yifeng Pharmacy and Laobaiqing, with attention to Yixintang [2]

Core Insights - The biomanufacturing sector is gaining momentum with strong policy support and technological advancements, positioning it as a key future industry in China [1][2] - The market size of China's biomanufacturing industry is projected to reach approximately 1.8 trillion yuan by 2030, with significant contributions from food additives and biopharmaceuticals [1][2] Industry Developments - The Ministry of Industry and Information Technology has reported that during the 14th Five-Year Plan, China's biomanufacturing industry is expected to expand steadily, reaching a total scale of 1.1 trillion yuan, with bioproducts accounting for over 70% of global production [1] - The focus of the 14th Five-Year Plan is on the industrialization of technology, emphasizing pilot testing, process scaling, and demonstration line construction [2] Company Initiatives - Ruipu Biotech is investing 680 million yuan in a large-scale microbial protein industrialization demonstration project, aiming for trial production by Q4 2026 [3] - Fuxiang Pharmaceutical is leveraging its expertise in high-end antibiotic fermentation to enhance its microbial protein project, focusing on domestic and international expansion [4] - Yikela Biotech is targeting high-value aquatic feed proteins through a collaboration with Fudan University, aiming to reduce reliance on imported fishmeal [5] Technological Advancements - Synthetic biology is identified as a core technology driving low-carbon production and increased labor productivity across various sectors, including healthcare and industrial manufacturing [2] - The integration of AI with synthetic biology is expected to shift the competitive landscape from single-point breakthroughs to platform-based competition, enhancing R&D efficiency [7] Market Trends - The most promising sub-sectors in biomanufacturing during the 14th Five-Year Plan include high-value biomanufactured products in healthcare, bio-based materials, and service-oriented platforms [6] - The industry is anticipated to experience differentiation and improved quality as companies focus on scalable processes, cost control, and clear downstream applications [2][6]

作为未来产业之一，生物制造赛道近期多点开花、动能充沛。政策层面持续加码，上海市近期印发行动 方案，将生物制造纳入积极引导的新兴产业领域，确立其战略优先级；企业端积极发力，富祥药业通过 成立跨国合资公司推进微生物蛋白全球化布局；科研前沿同步突破，"合成高等生物"先导项目启动，AI 驱动下的生命科学创新持续深化，多方协同发力激活万亿产业新潜力。 ● 本报记者 傅苏颖 万亿赛道根基渐牢 近年来，政策高度聚焦产业化落地与技术突破，形成多层次支撑体系，促进我国生物制造产业蓬勃发 展。 工信部此前披露，"十四五"期间，我国生物制造产业规模稳步扩大，总规模达1.1万亿元，生物发酵产 品产量占全球70%以上。其中食品及添加剂、生物制药等细分领域年产值超4000亿元，推动生物制造成 为新的经济增长点。易凯资本预测，到2030年，中国生物制造市场规模将会接近1.8万亿元。 长城证券化工新材料首席分析师肖亚平在接受中国证券报记者采访时表示，合成生物学技术作为生物制 造的核心支撑，可推动产业实现低碳生产、提升劳动生产率，其成果广泛应用于医疗健康、能源开发、 环境保护、工业制造等多个领域，为解决人类面临的各类发展挑战提供创新解决方案， ...

Core Viewpoint - The stock of Dermei Chemical has experienced a consecutive two-day limit-up, indicating strong market interest and potential growth driven by various factors [1] Group 1: Stock Performance - Dermei Chemical's stock reached a limit-up at 10:11 AM today, with a trading volume of 720 million yuan and a turnover rate of 18.35% [1] Group 2: Growth Drivers - The company's subsidiary is utilizing synthetic biology technology through a joint venture to implement biological enzyme methods, aligning with the low-carbon transition trend [1] - Dermei Chemical is investing in the quantum computing sector through an industrial fund, which is in line with cutting-edge technology trends [1] - The company's products are classified as bio-based materials, which resonate with national policies promoting green manufacturing, potentially benefiting from policy-driven expectations [1]

Group 1: Medical Aesthetics Industry - The Chinese medical aesthetics market is expected to reach nearly 370 billion yuan by 2025, with a compound annual growth rate (CAGR) of approximately 10% projected until 2030, potentially reaching 600 billion yuan [2][8][36] - The trend of "self-pleasure consumption" is prominent, with about 50% of users indicating that the reason for choosing medical aesthetics is that "becoming beautiful makes them happier" [8][11][15] - The consumer demographic is shifting towards younger individuals, with the proportion of users under 25 years old increasing from 26% in 2022 to 35% by 2025 [20][22][36] - Light medical aesthetics are becoming mainstream, accounting for 52% of the market in 2022, with a growing preference for non-invasive procedures [16][17][36] - The market for recombinant collagen is expected to grow significantly, with a projected CAGR of 41.4% from 2023 to 2027, potentially reaching 114.5 billion yuan [8][45] Group 2: Beauty Industry - The retail sales of cosmetics in China are projected to grow at a CAGR of approximately 9% from 2016 to 2024, with a moderate recovery expected in 2025 [3][9] - The trend of "self-gifting" is becoming the primary scenario for beauty consumption, reflecting the strengthening of "self-pleasure consumption" [3][8] - The cosmetics raw materials market is expected to grow from 1147.8 billion yuan in 2019 to 1603.9 billion yuan by 2024, with a CAGR of 6.9% [3][9] - The ODM (Original Design Manufacturer) industry for cosmetics is projected to reach 62.29 billion yuan by 2025, with domestic brands gaining market share [3][9] Group 3: Related Companies on the Beijing Stock Exchange - Companies such as Jinbo Biological, which leads in recombinant collagen medical devices and is entering the functional skincare market, are expected to benefit from the ongoing growth in the beauty consumption sector [3][8] - Bawei Co., which provides ODM services for domestic and international cosmetic brands, is also positioned to gain from the industry's expansion [3][8] - Leading companies in cosmetic raw materials, such as Weiqi Technology and Jiakai Biological, are well-placed to capitalize on the industry's growth [3][8]

中新网天津2月6日电 (记者 王君妍)记者6日从天津港保税区获悉，由中国科学院天津工业生物技术研究 所(以下简称天津工生所)牵头承担的国家重点研发计划"合成生物学"重点专项——"基于虚拟细胞技术的 合成基因回路与底盘细胞协同设计"项目启动会日前在天津举行。 项目启动会上，项目及课题负责人围绕项目背景、总体设计、研究内容、技术路线及最新进展等方面进 行了系统汇报。咨询专家组充分肯定了项目的前沿定位和交叉融合特色，并就虚拟细胞模型构建策略、 人工智能与机理模型融合路径、面向细胞工厂与细胞治疗应用的关键技术突破等提出了建设性意见。 天津工生所所长向华表示，该项目的实施，将有助于提升我国在生物设计底层工具与核心模型的创新能 力，为抢占下一代生物制造制高点提供有力支撑。 天津港保税区相关负责人表示，作为天津大力发展合成生物创新策源、推动生物制造产业高质量发展的 重要承载地，天津港保税区全力打造"生物制造先导区"，并已在区域内构建起以天津工生所、国家合成 生物技术创新中心等平台为核心的研发策源体系，涌现出二氧化碳人工合成淀粉、DNA合成仪、健康 糖等一批标志性项目。(完) 据介绍，该项目聚焦合成生物学与人工智能前沿交叉领 ...

Group 1 - The company announced the approval of a synthetic biology manufacturing project in Xinjiang, with a total investment of 1 billion yuan, to be constructed in three phases [2][5] - The project aims to meet market demand, overcome capacity and efficiency bottlenecks, and achieve technological upgrades and cost control [2][6] - The project aligns with the encouraging industrial policies of the western region, allowing the company to benefit from local tax incentives and meet green development requirements [2][6] Group 2 - The company specializes in the animal health sector, focusing on the research, production, and sales of veterinary drugs, feed, and additives [4][8] - The company has achieved full coverage in the top 10 of the national pig farming industry and has established stable partnerships with many large domestic farming enterprises [5][8] - The projected sales revenue for 2024 is 1.2 billion yuan, representing a year-on-year growth of 17.71% [5][8] - The company currently has a production capacity of 2,000 tons for Tylosin and 840 tons for Tiamulin [5][8]